Why the study?
Sotatercept has shown improvements in patients with PAH, prompting a meta-analysis of RCTs to evaluate its overall efficacy.
Does sotatercept improve six-minute walk distance, WHO functional class, and pulmonary vascular resistance in patients with pulmonary arterial hypertension on background therapy?
Population
429 patients with PAH on background therapy across 2 RCTs
Comparison
Sotatercept vs placebo
Design
Meta-analysis of RCTs
Key result
Sotatercept significantly improved the six-minute walk distance by a mean difference of 34.99 meters compared to placebo in patients with pulmonary arterial hypertension.
Authors
Loading...
Supports adding sotatercept to background PAH therapy; extends prior trial data on exercise capacity and hemodynamics.
Meta-Analysis (n=429)
Does sotatercept improve six-minute walk distance, WHO functional class, and pulmonary vascular resistance in patients with pulmonary arterial hypertension on background therapy?
Effect estimate: MD 34.99 (95% CI 19.02-50.95)
p-value: p=< 0.0001
Sotatercept added to background therapy significantly improves exercise capacity, functional class, and pulmonary hemodynamics in patients with pulmonary arterial hypertension.
Uddin et al. (2024) conducted a meta-analysis in Pulmonary arterial hypertension (n=429). Sotatercept vs. Placebo was evaluated on Six-minute walk distance (MD 34.99, 95% CI 19.02-50.95, p=< 0.0001). Sotatercept significantly improved the six-minute walk distance by a mean difference of 34.99 meters compared to placebo in patients with pulmonary arterial hypertension.